Skip to main content
Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.410
-0.070 (-2.01%)
At close: Apr 28, 2026, 4:00 PM EDT
3.390
-0.020 (-0.59%)
After-hours: Apr 28, 2026, 7:59 PM EDT

Recursion Pharmaceuticals Revenue

In the year 2025, Recursion Pharmaceuticals had annual revenue of $74.68M with 26.92% growth. Recursion Pharmaceuticals had revenue of $35.54M in the quarter ending December 31, 2025, with 681.74% growth.

Revenue (ttm)
$74.68M
Revenue Growth
+26.92%
P/S Ratio
24.12
Revenue / Employee
$124,468
Employees
600
Market Cap
1.80B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202574.68M15.84M26.92%
Dec 31, 202458.84M14.26M32.00%
Dec 31, 202344.58M4.73M11.88%
Dec 31, 202239.84M29.67M291.46%
Dec 31, 202110.18M6.22M156.89%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Galapagos NV 1.31B
Harmony Biosciences Holdings 868.45M
Innoviva 411.33M
Vericel 276.26M
AnaptysBio 234.60M
Syndax Pharmaceuticals 172.35M
Taysha Gene Therapies 9.77M
Inhibrx Biosciences 1.30M
Revenue Rankings

RXRX News

More News